Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: gao seng who wrote (427)	6/13/2000 2:07:00 AM
From: allen menglin chen	Read Replies (1) \| Respond to of 746

Celera Speeds to the Finish in Genetic Code Sequencing Race June 12, 2000 Print Story Bob Woods, Washtech.com E-Mail Story ROCKVILLE, Md. - Genomic information management and analysis software Celera Genomics [NYSE:CRA], one of two groups racing to crack the human genetic code, reportedly said a rough draft of its work has now been completed. London's Daily Telegraph quoted officials from Rockville, Md.-based Celera as saying the "sequencing phase of the genome from one human being...(had been) completed," and that an announcement regarding the rough draft was forthcoming. Celera Genomics is competing against the Human Genome Project, an international group that receives its funding from public sources. A spokesperson for the Project told the Daily Telegraph said it too had completed the draft. But formal announcements regarding the drafts are about a week or so away, the paper also said. A Japanese newspaper, meantime, quoted Celera President J. Craig Venter, Ph.D., as saying the company would complete human genome sequencing by the end of this month. And today, Celera said it entered into a pact with Geron Corp. to combine Geron's expertise in human pluripotent stem cell biology with Celera's comprehensive sequencing information and gene discovery capabilities. Financial terms were not disclosed. The objective of the collaboration is to identify and assign function to genes important in early human development, and to utilize the information to develop small molecule pharmaceuticals, protein therapeutics, cell and gene therapies, diagnostics, and tools for use in drug discovery and testing, according to a statement. E-mail (via our form \| via your e-mail client) comments, suggestions, etc. to Editor-in-Chief Bob Woods. Copyright?2000 Post-Newsweek Business Information, Inc. All Rights Reserved bart.washtech.com